Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Completed
141 enrolled 37 charts
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Completed
26 enrolled
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Phase 1 Completed
48 enrolled 13 charts
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
23 enrolled
AML1208
Phase 1 Completed
11 enrolled
AML
Phase 1 Completed
10 enrolled
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase 1 Completed
50 enrolled
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Phase 1 Completed
22 enrolled
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
25 enrolled
UPCC 02407
Phase 1 Completed
16 enrolled
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
30 enrolled
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
Phase 1 Completed
42 enrolled
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
67 enrolled
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Phase 1 Completed
29 enrolled
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
24 enrolled
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
Phase 1 Completed
25 enrolled
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Completed
34 enrolled
Lenalidomide Plus Chemotherapy for AML
Phase 1 Completed
36 enrolled
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
3 enrolled
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Phase 1 Completed
13 enrolled
Vandevol
Phase 1 Completed
20 enrolled
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Phase 1 Completed
7 enrolled
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase 1 Completed
47 enrolled
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection
Phase 1 Completed
20 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
35 enrolled
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase 1 Completed
3 enrolled
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Phase 1 Completed
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Phase 1 Completed